YIDU TECH (02158) has repurchased shares for two consecutive days, spending nearly 3 million Hong Kong dollars.

YIDU TECH (2158) announced that on December 4th, the company repurchased 181,000 shares at an average price of HK$5.15 per share, with a total repurchase amount exceeding HK$930,000. This marks the second consecutive day of repurchases, with a total of approximately 573,000 shares repurchased and a cumulative repurchase amount of nearly HK$3 million. Since September 26th, the company has completed 12 repurchase transactions, with a total repurchase amount exceeding HK$25 million. In recent news, YIDU TECH recently released its mid-term performance for the 2026 fiscal year and held a performance presentation. The report showed that during the reporting period, YIDU TECH's business maintained healthy growth, with total revenue reaching RMB 358 million, an 8.7% year-on-year increase. The company achieved significant milestones in profit quality and operational efficiency: Adjusted EBITDA for existing business reached approximately RMB 54 million, doubling from the same period last year, approaching breakeven at the accounting level. The achievement of this key financial milestone came about a year earlier than expected by the company's management. During the performance presentation, the company's management pointed out that its medical AI technology has entered a new stage of "multi-point blossoming and scaled implementation." This is mainly reflected in three dimensions: Firstly, its AI platform has been deeply deployed in more than 30 top-tier tertiary hospitals nationwide, with the "Copilot" assistance tool for clinical doctors achieving nearly a thousand high-frequency calls per day in a single hospital, already integrated into actual workflows. Secondly, the empowerment effects for key specialties such as oncology are significant, with the accuracy of its TNM staging evaluation intelligent body (such as the accuracy of T staging increasing from 58% to 90%) reaching the level of chief physicians. Thirdly, by creating a "digital avatar" for top doctors, the company is attempting to more widely empower grassroots healthcare with scarce expert experience, exploring a new model for the inheritance and accessibility of medical wisdom. On the capital market front, brokerage institutions have been sending positive signals. EB SECURITIES noted in its tracking research report that YIDU TECH continues to break through in the field of AI medical innovation, with its medical AI model preliminarily constructing a "data + algorithm + scenario" flywheel closed-loop, accelerating the application of technology in multiple scenarios. Citigroup also issued a report maintaining a "buy" rating on the company with a target price of HK$10, fully recognizing its core competitiveness and growth potential in the AI medical track. As of the close of the day, YIDU TECH's stock price was HK$5.15, up 0.98%.